Heart involvement in systemic sclerosis

##plugins.themes.academic_pro.article.sidebar##

Published Dec 11, 2017
Download
pdf
Vol. 95 No. 3 (2017): Issue Mar 2017

##plugins.themes.academic_pro.article.main##

Ihsen Zairi
Lilia Baili
Khadija Mzoughi
Manel Dridi
Zouhaier Jnifene
Fatma Boussema

Abstract

Introduction: Primary and secondary heart involvement in systemic sclerosis are important mortality predictors.
Aim of this study was to investigate by standard echocardiography associated to pulsed-tissue Doppler imaging, six-minute walk test (6MWT) and BNP level cardiac manifestation in 30 patients with ScS and to establish a strategy to detect and to evaluate this complication.
Methods: This was a cross-sectional study conducted over a period of 16 months: a total of 30 consecutive patients with ScS diagnosed as proposed by the American college of Rheumatology and the European League Against Rheumatism 2013 and who were hospitalized in Internal Medicine department of Habib Thameur hospital underwent cardiac assessment.
Results: Twenty-nine patients were female, the mean age of diagnosis was 46 years ± 13,49  [18-71 years]. Echocardiography found left ventricular systolic dysfunction (LVSD) on tissue doppler imaging, in 40% of cases, it was significantly associated with diffuse ScS (p=0,024), with Scl70 anti bodies (p=0,043) and interstitial lung disease (p=0,024). However, the left ventricular diastolic dysfunction (LVDD) was correlated with a high diastolic arterial hypertension (p=0,028), diffuse ScS (0,048), telangiectasia (p=0,029) and pulmonary hypertension (p=0,033). Higher systolic pulmonary arterial pressure (PAPs) (p=0,029) and higher BNP level (p=0,027) were noted in the group of patients with right ventricular systolic dysfunction (RVSD). Patients who had an elevated PAPs had: accelerated pulse (p=0,022), a cough (p=0,024), dyspnea III-IV (p=0,003), shorter six-minute walk distance (p=0,044), greater Borg score (p=0,025) and elevated BNP level (p=0,015). Thus, a positive correlation was found between PAPs and BNP (p=0,004, r=+0,53), a negative correlation was noted between PAPs and ST (p=0,006, r=-0,49). The ROC curve identified a discriminator threshold for ST<11,5cm/s (BNP ≥43,5pg/l) and PAPs >35mmHg (BNP ≥92pg/l). A discriminator value of the 6MWD (≥294m) was recorded for a PAPs >35mmHg. 2000-3000 salma

Conclusion: Left ventricular diastolic impairment was the most frequent echographic abnormality in our study. The BNP level and 6MWT are sensitive and specific in the detection of an elevation of PAPs.

Keywords:

Systemic sclerosis, Ventricular dysfunction, Pulmonary hypertension, Echocardiography, Brain natriuretic peptide

##plugins.themes.academic_pro.article.details##

References

  1. D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969; 46: 428-40.
  2. Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis. 2013; 72: 1747-55.
  3. Hachulla E, Launay D. Sclérodermie systémique. Encycl Med Chir. Appareil locomoteur. 2005 : 21.
  4. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: are port from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a Branch of the european Socity of Cardiology. J Am Sac Echocardiogr. 2005; 18: 1440-63.
  5. Mor-Avi V, Lang RM, Badano LP, et al. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. J Am Soc Echocardiogr. 2011; 24: 277-313.
  6. Dridi I. Atteinte cardiaque et vasculaire pulmonaire au cours de la sclérodermie systémique : A propos de 40 cas [Thèse]. Médecine: Tunis ; 2014.
  7. Ben khlifa M. Sclérodermie systémique dans un service de Médecine Interne étude à propos de 36 patients [thèse]. Médecine: Tunis ; 2011.
  8. Ranque B, Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev. 2010: 311
  9. .Zandman-Goddard G. Systemic Sclerosis. Ann Rheum Dis. 2009; 68: 620.
  10. Marie I. Atteinte digestive au cours de la Sclerodermie Systemique. Press med. 2006; 35: 1952-65.
  11. Cozzi F, Marson P, Cardarelli S, Favaro M, Tison T, Tonello M et al. Prognosis of scleroderma renal crisis: a long-term observational study. Nephrol Dial Transplant. 2012; 27: 4398-403.
  12. Launy D, Hachulla E. Atteintes cardiaques et pulmonaires sclérodermiques. Rev Prat. 2002, 52: 1901-7.
  13. Ferri C, Emdin M, Nielsen H, Bruhlmann P. Assessment of heart involvement. Clin Exp Rheumatol. 2003; 21: 24-8.
  14. Maione S, Cuomo G, Giunta A, Tanturri de Horatio L, La Montagna G, Manguso F et al. Echocardiographic alterations in systemic sclerosis: a longitudinal study. Semin Arthritis Rheum. 2005; 34: 721-7.
  15. De Groote P,GressinV, HachullaE, CarpentierP, GuillevinL, KahanA, et al. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis. 2008; 67: 31-6.
  16. Poanta L, Dadu R, Tiboc C, Rednic S, Dumitrascu D. Systolic and diastolic function in patients with systemic sclerosis. Eur J Intern Med. 2009; 20: 378-82.
  17. Allanore Y, Meune C, Vonk MC, Airo P, Hachulla E, Caramaschi P et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis. 2010; 69: 218-21.
  18. D'Andrea A, Stisi S, Bellissimo S, Vigorito F, Scotto di Uccio F, Tozzi N et al. Early impairment of myocardial function in systemic sclerosis: non-invasive assessment by Doppler myocardial and strain rate imaging. Eur J Echocardiogr. 2005; 6: 407-18.
  19. Meune C, Avouac J, Wahbi K, Cabanes L, Wipff J, Mouthon L, et al. Cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography during routine care: a controlled study of 100 consecutive patients. Arthritis Rheum. 2008; 58: 1803-9.
  20. Launay D, De Groote P, Gaxotte V, Charlanne H, Beregi JP, Hatron PY et al. Atteinte cardiaque de la sclérodermie systémique. MT Cardio. 2006; 2: 339-54.
  21. Garnier R, Bazire A, Chataigner D. Sclérodermie et exposition professionnelle aux Solvants organiques. Arch Mal Prof. 2006; 67: 488-504.
  22. Sohn DW, Chai IH, Lee DJ, Kim HC, Lee MM, Oh BH et al. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol. 1997; 30: 474-80.
  23. Fernandes F, Ramires FJ, Arteaga E, Ianni BM, Bonfa ES, Mady C. Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. J Card Fail. 2003; 9: 311-7.
  24. Forfia PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006; 174: 1034-41.
  25. Lindqvist P, Caidahl K, Neuman-Andersen G, Ozolins C, Rantapää-Dahlqvist S, Waldenström A et al. Disturbed right ventricular diastolic function in patients with systemic sclerosis: a Doppler tissue imaging study. Chest. 2005; 128: 755-63.
  26. Schattke S, Knebel F, Grohmann A, Dreger H, Kmezik F, Riemekasten G et al. Early right ventricular systolic dysfunction in patients with systemic sclerosis without pulmonary hypertension: a Doppler Tissue and Speckle Tracking echocardiography study. Cardiovasc Ultrasound. 2010; 8: 3.
  27. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006; 173: 1023-30.
  28. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005; 52: 3792-800.
  29. Güllülü S, Kaderli AA, Ekbul A, Ozdemir B, Baran I, Güllülü M et al. Tissue Doppler echocardiography and myocardial performance index in patients with scleroderma. J Int Med Res. 2005; 33: 417-24.
  30. Candell-Riera J, Armadans-Gil L, Simeon CP, Castell-Conesa J, Fonollosa-Pla V, García-del-Castillo H et al. Comprehensive non invasive assessment of cardiac involvement in limited systemic sclerosis. Arthritis Rheum. 1996; 39: 1138-45.
  31. Zelepis GE, Kelekis NL, Plastiras SC, Mitseas P, Economopoulos N, Kampolis C et al. Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed enhanced magnetic resonance imaging study. Arthritis Rheum. 2007; 56 (11): 3827-36.
  32. Martinez-Rumayor A, Richards AM, Burnett JC JR.: Biology of the natriuretic peptides. Am J Cardiol. 2008; 101: 3-8.
  33. Allanore Y, Borderie D, Meune C, Cabanes L, Weber S, Ekindjian OG, Kahan A, N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Arthritis Rheum. 2003; 48: 3503-8
  34. Murkerjee D, Yap LB, Holmes AM , Nair D, Ayrton P, Black CM, Coghlan JG. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med. 2003; 97: 1230-6.
  35. Cavagna L, Caporali R, Klersy C, Ghio S, Albertini R, Scelsi L et al. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis. J Rheumatol. 2010; 37: 2064-70.
  36. Leite MA, Pereira MC, Costallat LT, Villalba Wde O, Moreira MM, Paschoal IA Evaluation of respiratory impairment in patients with systemic lupus erythematosus with the six-minute walk test. Rev Bras Reumatol. 2014; 54: 192-9.
  37. Villalba WO, Sampaio-Barros PD, Pereira MC, Cerqueira EM, Leme CA Jr, Marques-Neto JF et al. Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. Chest. 2007; 131: 217-22.
  38. Avouac J, Airò P, Meune C, Beretta L, Dieude P, Caramaschi P et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol. 2010; 37 (11): 2290-8.
  39. Allanore Y, Meune C, Vignaux O, Weber S, Legmann P, Kahan A. Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and tissue-Doppler echography study. J Rheumatol. 2006; 33: 2464-9.